Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belvarafenib in BRAF-Altered Primary and Metastatic Brain Tumors
NCT07688356Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of Belvarafenib in primary brain tumor, brain tumor, sponsored by Samsung Medical Center. Started Jun 2026; status: recruiting.
02
Drugs
Belvarafenib
03
Conditions
primary brain tumorbrain tumor
Beyond the preview
Go deeper on NCT07688356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688356.